Karyopharm Therapeutics Inc (KPTI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.79+1.13%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KPTI
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(-1.8) + peer(0.2*0.0) + term(0.0) → -0.63% (capped ±15.0)
Calibrated likelihood the company misses analyst consensus on its next print, read from its own miss history plus its industry base rate. A fundamental tilt, not a price call — and a quiet watch-flag, not an alarm.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Calibrated. Base rate ~24%.
Consecutive quarters it missed, most recent run.
How often this industry misses, baseline.
Industry peers that missed in the recent window.
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On August 13, 2026, Karyopharm Therapeutics Inc. announced its financial results for the quarter ended June 30, 2026 and that it will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The informatio…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On May 14, 2026, Karyopharm Therapeutics Inc. announced its financial results for the quarter ended March 31, 2026 and that it will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information…
Results of Operations and Financial Condition. On February 12, 2026, Karyopharm Therapeutics Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025 and that it will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein b…
Results of Operations and Financial Condition. On January 12, 2026, Karyopharm Therapeutics Inc. (the “Company”) announced its preliminary unaudited total revenue and U.S. XPOVIO ® (selinexor) net product revenue estimates for the fourth quarter and full year ended December 31, 2025 announced its preliminary unaudited cash, cash equivalents, restricted cash and investments as of December 31, 2025, and outlined its 2025 achievements and 2026 objectives. The full text of the press release issue…
Results of Operations and Financial Condition. On November 3, 2025, Karyopharm Therapeutics Inc. announced its financial results for the quarter ended September 30, 2025 and that it will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The info…
Results of Operations and Financial Condition. On October 7, 2025, the Company issued a press release that included preliminary estimates of the Company’s total revenue and U.S. XPOVIO ® (selinexor) net product revenue for the three months ended September 30, 2025 and a preliminary estimate of the Company’s cash, cash equivalents, restricted cash and investments as of September 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1…
Results of Operations and Financial Condition. On August 11, 2025, Karyopharm Therapeutics Inc. announced its financial results for the quarter ended June 30, 2025 and that it will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The informatio…
Results of Operations and Financial Condition. On May 12, 2025, Karyopharm Therapeutics Inc. announced its financial results for the quarter ended March 31, 2025 and that it will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information…
Results of Operations and Financial Condition. On February 19, 2025, Karyopharm Therapeutics Inc. announced its financial results for the fourth quarter and full year ended December 31, 2024 and that it will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein b…
shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press Release issued by Karyopharm Therapeutics Inc. on January 13, 2025 104 Cover Page Interactive Data File (formatted as Inline XBRL) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KARYOPHARM THERAPEUTICS INC. Date: January 13, 2025 By: /s/ Michael Mano Michael Mano Se…
Results of Operations and Financial Condition. On November 5, 2024, Karyopharm Therapeutics Inc. announced its financial results for the quarter ended September 30, 2024 and that it will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The info…
Results of Operations and Financial Condition. On August 6, 2024, Karyopharm Therapeutics Inc. announced its financial results for the quarter ended June 30, 2024 and that it will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information…
Results of Operations and Financial Condition. On May 8, 2024, Karyopharm Therapeutics Inc. announced its financial results for the quarter ended March 31, 2024 and that it will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information p…
Results of Operations and Financial Condition. On February 29, 2024, Karyopharm Therapeutics Inc. announced its financial results for the fourth quarter and full year ended December 31, 2023 and that it will conduct a previously announced, publicly available conference call to discuss those results and other company updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein b…
shall be deemed to be furnished, and not filed: 99.1 Press release issued by Karyopharm Therapeutics Inc. on January 8, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KARYOPHARM THERAPEUTICS INC. Date: January 8, 2024 By: /s/ Michael Mano Michael Mano Senior Vice President, Gener…